Glycogen storage disease type II (NORD)
00:00 / 00:00
Videos
Notes
Glycogen storage disease type II (NORD)
Information for patients and families
Glut1 Deficiency Foundation
Glut1 deficiency syndrome (Glut1 Deficiency Foundation)
Gorlin Syndrome Alliance
Gorlin syndrome (Gorlin Syndrome Alliance)
The National Organization for Rare Disorders (NORD)
Recurrent pericarditis (NORD)
Autoimmune polyglandular syndrome type 1 (NORD)
Opsoclonus myoclonus syndrome (NORD)
Thyroid eye disease (NORD)
Bile synthesis disorders (NORD)
Cyclic vomiting syndrome (NORD)
Eosinophilic esophagitis (NORD)
Short bowel syndrome (NORD)
Essential thrombocythemia (NORD)
Myelofibrosis (NORD)
Polycythemia vera (NORD)
Sickle cell disease (NORD)
Waldenstrom macroglobulinemia (NORD)
Warm autoimmune hemolytic anemia and cold agglutinin (NORD)
Congenital athymia (NORD)
Cytomegalovirus infection after transplant (NORD)
Post-transplant lymphoproliferative disorders (NORD)
Severe chronic neutropenia (NORD)
Adrenoleukodystrophy (NORD)
Alagille syndrome (NORD)
Aromatic L-amino acid decarboxylase deficiency (NORD)
Cerebrotendinous xanthomatosis (NORD)
Classical homocystinuria (NORD)
Congenital cytomegalovirus (NORD)
Cystinuria (NORD)
Fabry disease (NORD)
Gaucher disease (NORD)
Glycogen storage disease type II (NORD)
Metachromatic leukodystrophy (NORD)
Mucopolysaccharide storage disease type 1 (Hurler syndrome) (NORD)
Mucopolysaccharide storage disease type 2 (Hunter syndrome) (NORD)
Mycobacterium avium complex (NORD)
NGLY1 deficiency (NORD)
Niemann-Pick disease types A and B (NORD)
Phenylketonuria (NORD)
PIK3CA-related overgrowth spectrum (NORD)
Tay-Sachs disease (NORD)
Zellweger spectrum disorders (NORD)
Early infantile epileptic encephalopathy (NORD)
Opsoclonus myoclonus syndrome (NORD)
Spinocerebellar ataxia (NORD)
Narcolepsy (NORD)
Focal segmental glomerulosclerosis (NORD)
IgA nephropathy (NORD)
Pulmonary arterial hypertension (NORD)
The Primary School
ADHD: Information for patients and families (The Primary School)
Asthma: Information for patients and families (The Primary School)
Childhood nutrition and obesity: Information for patients and families (The Primary School)
Childhood oral health: Information for patients and families (The Primary School)
Food allergies and EpiPens: Information for patients and families (The Primary School)
Toxic stress: Information for patients and families (The Primary School)
Assessments
Glycogen storage disease type II (NORD)
Flashcards
0 / 11 complete
USMLE® Step 1 questions
0 / 3 complete
High Yield Notes
7 pages
Flashcards
Glycogen storage disease type II (NORD)
of complete
Questions
USMLE® Step 1 style questions USMLE
of complete
External References
First Aid
2022
2021
2020
2019
2018
2017
2016
Cardiomegaly
Pompe disease p. 85
Hypertrophic cardiomyopathy p. 317
Pompe disease p. 85
Pompe disease p. 85
Transcript
Content Reviewers
Contributors
Pompe disease, also called glycogen storage disease type II, is a genetically inherited condition caused by insufficient functioning of an enzyme called lysosomal acid alpha-1,4-glucosidase, or just acid alpha-glucosidase, and it’s caused by a mutation of the GAA gene. It’s named after the Dutch pathologist, Dr. J.C. Pompe, who first described it in 1932.
Glucose is used for energy by most cells of the body, and it’s stored inside the cells as a compact, branch-shaped molecule called glycogen. When a cell needs energy, it uses enzymes to remove glucose molecules from the branches. One of the organelles within the cell is the lysosome, which functions a bit like a tiny recycling plant. The lysosome contains enzymes that break down cellular substances so that they can be recycled. Now for some reason, and it’s not really understood why, but small amounts of glycogen end up in the lysosomes, where it’s broken down by an enzyme called acid alpha-glucosidase, to release glucose from the glycogen chain.
In Pompe disease, a mutation of the GAA gene prevents the production of enough functional acid alpha-glucosidase, and as a result, lysosomes can’t break down glycogen. This leads to a buildup of glycogen within the cytoplasm and lysosomes, and that leads to cellular damage and destruction.
Now, normally, glycogen is found in the largest amounts in the cytoplasm of liver cells and all three types of muscle cell. In individuals with Pompe, glycogen mostly accumulates in the lysosomes of those cells. Skeletal muscles include various muscles of the body as well as the diaphragm which is the primary breathing muscle. Cardiac muscle makes up the majority of the heart, and smooth muscle is found in the walls of blood vessels and many other organs.
Pompe disease is an autosomal recessive condition - so in other words, both parents must be carriers. The severity of the condition depends on how much functional acid alpha-glucosidase is produced. If little to no enzyme exists, the infantile-form of the condition typically occurs. Within the first few months of life, muscular damage to the heart develops, causing hypertrophic cardiomyopathy or an enlarged heart and eventual heart failure. Skeletal muscle weakness causes severely decreased muscle tone of the entire body. Weakness of the diaphragm and other breathing muscles lead to respiratory failure as well. Other findings include an enlarged liver which is thought to be largely due to heart failure, and a large tongue, which is primarily made of muscle.
For Institutions
Copyright © 2023 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Cookies are used by this site.
USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.
